Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer
The trial evaluates the combination of cabozantinib and panitumumab in KRAS wild-type metastatic colorectal cancer (CRC) and cabozantinib monotherapy in MET amplified CRC. Given the high unmet need in treatment-refractory CRC, successful outcomes could position this combination as a competitive option in the oncology market. The trial's completion in 2018 suggests that data may be available for further analysis, which could influence strategic partnerships or acquisitions in the oncology space. The involvement of Exelixis indicates potential commercial interest in the cabozantinib franchise, which could enhance market positioning if results are favorable.
Indication: Colorectal Cancer
Modality: protein therapy
Target: MET gene amplification and EGFR signaling pathway (targeted by panitumumab)
Sponsor: John Strickler, M.D.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: MET gene amplification and EGFR signaling pathway (targeted by panitumumab)
View original source fields
Condition raw: Colorectal Cancer
Condition normalized: Colorectal Cancer
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: MET gene amplification and EGFR signaling pathway (targeted by panitumumab)
Target normalized: MET gene amplification and EGFR signaling pathway (targeted by panitumumab)